医学
心肌梗塞
内科学
危险系数
心脏病学
安慰剂
临床终点
载脂蛋白B
冲程（发动机）
置信区间
胆固醇
随机对照试验
机械工程
工程类
病理
替代医学
作者
C. Michael Gibson,Danielle Duffy,Serge Korjian,M. Cecilia Bahit,Gerald Chi,John H. Alexander,A. Michael Lincoff,Mark Heise,Pierluigi Tricoci,Lawrence I. Deckelbaum,Sojaita Jenny Mears,José Carlos Nicolau,Renato D. Lópes,Béla Merkely,Basil S. Lewis,Jan H. Cornel,Jarosław Trębacz,Alexander Parkhomenko,Peter Libby,Frank M. Sacks
标识
DOI：10.1056/nejmoa2400969
摘要
Among patients with acute myocardial infarction, multivessel coronary artery disease, and additional cardiovascular risk factors, four weekly infusions of CSL112 did not result in a lower risk of myocardial infarction, stroke, or death from cardiovascular causes than placebo through 90 days. (Funded by CSL Behring; AEGIS-II ClinicalTrials.gov number, NCT03473223.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
null
散逸层梦游
学术雷锋
吃葡萄不吐葡萄皮
Criminology34
北白川anko
飘逸的大雁
sanvva
Chinlu_Lee
sxlen
v0id
学霸业
无极微光
Gp1983
HuiLang
madeleinli
czx
宇王
dtg
年年有余
皖公网安备34019202002308
